[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 23/30, 2005

Rhabdomyolysis and Lipid-Lowering Drugs

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(12):1448-1449. doi:10.1001/jama.293.12.1448-a

To the Editor: In their study on rhabdomyolysis in patients treated with lipid-lowering drugs, Dr Graham and colleagues1 reported that, compared with statin monotherapy, the use of fibrates alone was associated with a 5.5-fold increase in the risk of rhabdomyolysis requiring hospitalization and the combined use of a statin and fibrate resulted in an additional increase in this risk, especially in older patients with diabetes mellitus. These risks were most pronounced for cerivastatin compared with other statins, both when it was used as monotherapy and when used in combination with a fibrate.

First Page Preview View Large
First page PDF preview
First page PDF preview
×